Lilly's Cyramza misses in second-line HCC

Eli Lilly and Co. (NYSE:LLY) said IV Cyramza ramucirumab plus best supportive care (BSC) as second-line treatment of hepatocellular carcinoma (HCC) missed the primary endpoint of improving overall survival (OS) vs. placebo plus BSC in the 565-patient Phase III REACH trial. Lilly said Cyramza plus BSC showed "meaningful improvements" on the secondary endpoints of progression-free survival (PFS), overall response rate (ORR) and time to progression vs. placebo plus BSC, but declined to disclose details. The pharma said it plans to discuss the REACH data with regulatory authorities. ...